![]() |
UMIN-CTR Clinical Trial |
|
![]() |
![]() |
![]() |
![]() |
Name: | UMIN ID: |
Recruitment status | No longer recruiting |
Unique ID issued by UMIN | UMIN000043299 |
Receipt No. | R000049415 |
Scientific Title | An ancillary biomarker study of Gio-Tag Japan. |
Date of disclosure of the study information | 2021/02/15 |
Last modified on | 2021/02/10 |
Basic information | ||
Public title | An ancillary biomarker study of Gio-Tag Japan. | |
Acronym | An ancillary biomarker study of Gio-Tag Japan. | |
Scientific Title | An ancillary biomarker study of Gio-Tag Japan. | |
Scientific Title:Acronym | An ancillary biomarker study of Gio-Tag Japan. | |
Region |
|
Condition | |||
Condition | Non-small cell lung cancer | ||
Classification by specialty |
|
||
Classification by malignancy | Malignancy | ||
Genomic information | YES |
Objectives | |
Narrative objectives1 | Identifying Factors that Make Patients Ready for Afatinib to Osimertinib Sequential Therapy |
Basic objectives2 | Others |
Basic objectives -Others | Biomarker study |
Trial characteristics_1 | Exploratory |
Trial characteristics_2 | |
Developmental phase | Not applicable |
Assessment | |
Primary outcomes | Comparison of T790M rate before and after treatment with afatinib.
|
Key secondary outcomes | Correlation between T790M rate before treatment with afatinib and response rate, progression-free survival, and overall survival of afatinib.
Correlation between the T790M rate before the treatment with afatinib and the transition rate to second-line treatment. Correlation between T790M rate before treatment with afatinib, and response rate and progression-free survival rate of second-line treatment. |
Base | |
Study type | Observational |
Study design | |
Basic design | |
Randomization | |
Randomization unit | |
Blinding | |
Control | |
Stratification | |
Dynamic allocation | |
Institution consideration | |
Blocking | |
Concealment |
Intervention | |
No. of arms | |
Purpose of intervention | |
Type of intervention | |
Interventions/Control_1 | |
Interventions/Control_2 | |
Interventions/Control_3 | |
Interventions/Control_4 | |
Interventions/Control_5 | |
Interventions/Control_6 | |
Interventions/Control_7 | |
Interventions/Control_8 | |
Interventions/Control_9 | |
Interventions/Control_10 |
Eligibility | ||||
Age-lower limit |
|
|||
Age-upper limit |
|
|||
Gender | Male and Female | |||
Key inclusion criteria | Patients enrolled in the main study (Gio-Tag Japan) (UMIN000037452) | |||
Key exclusion criteria | Patients with no residual specimens collected in the main study (Gio-tag Japan)
Patients whose data was rejected in the main study |
|||
Target sample size | 93 |
Research contact person | |||||||
Name of lead principal investigator |
|
||||||
Organization | Hyogo College of Medicine Hospital | ||||||
Division name | Respiratory Medicine | ||||||
Zip code | 663-8501 | ||||||
Address | 1-1,mukogawacho,nishinomiya | ||||||
TEL | 0798-45-6597 | ||||||
tkijima@hyo-med.ac.jp |
Public contact | |||||||
Name of contact person |
|
||||||
Organization | Hyogo College of Medicine Hospital | ||||||
Division name | Respiratory Medicine | ||||||
Zip code | 663-8501 | ||||||
Address | 1-1,mukogawacho,nishinomiya | ||||||
TEL | 0798-45-6597 | ||||||
Homepage URL | |||||||
ta-yokoi@hyo-med.ac.jp |
Sponsor | |
Institute | HANSHIN Oncology Group |
Institute | |
Department |
Funding Source | |
Organization | Nippon Boehringer Ingelheim Co.Ltd. |
Organization | |
Division | |
Category of Funding Organization | Profit organization |
Nationality of Funding Organization |
Other related organizations | |
Co-sponsor | |
Name of secondary funder(s) |
IRB Contact (For public release) | |
Organization | Hyogo College of Medicine |
Address | 1-1,mukogawacho,nishinomiya |
Tel | 0798-45-6066 |
rinri@hyo-med.ac.jp |
Secondary IDs | |
Secondary IDs | NO |
Study ID_1 | |
Org. issuing International ID_1 | |
Study ID_2 | |
Org. issuing International ID_2 | |
IND to MHLW |
Institutions | |
Institutions | 全国から約60施設 |
Other administrative information | |||||||
Date of disclosure of the study information |
|
Related information | |
URL releasing protocol | |
Publication of results | Unpublished |
Result | |
URL related to results and publications | |
Number of participants that the trial has enrolled | 93 |
Results | |
Results date posted | |
Results Delayed | |
Results Delay Reason | |
Date of the first journal publication of results | |
Baseline Characteristics | |
Participant flow | |
Adverse events | |
Outcome measures | |
Plan to share IPD | |
IPD sharing Plan description |
Progress | |||||||
Recruitment status | No longer recruiting | ||||||
Date of protocol fixation |
|
||||||
Date of IRB |
|
||||||
Anticipated trial start date |
|
||||||
Last follow-up date |
|
||||||
Date of closure to data entry | |||||||
Date trial data considered complete | |||||||
Date analysis concluded |
|
Other | |
Other related information | Retrospective observational study |
Management information | |||||||
Registered date |
|
||||||
Last modified on |
|
Link to view the page | |
URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049415 |
Research Plan | |
Registered date | File name |
Research case data specifications | |
Registered date | File name |
Research case data | |
Registered date | File name |